Endocyte (ECYT) : exclusive worldwide license of prostate cancer drug

  

• the following day:

Endocyte completes exclusive worldwide license of PSMA-617 from ABX GmbH

Highlights: 

• Transaction Provides Endocyte with the 'Most Advanced' Targeted Radioligand Therapy in Development for Prostate Cancer, Addressing a Greater than $1 Billion Market Opportunity
• High Response Rates were Demonstrated in Late Stage Prostate Cancer Patients in Clinical Data Presented at Recent European Society for Medical Oncology
• Endocyte will Focus Resources on Phase 3 Registration Trial Planned to Initiate in First Half 2018
• Investigator Initiated Trials Intend to Support Registration and Provide Ongoing Data Assessments